User:Megan Leaman/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 23: Line 23:
==Regulation==
==Regulation==
-
Regulation of DGAT1 is thought to be performed by the hydrophilic N-terminal domain which regulates activity based on acyl-CoA/CoA levels. The N-terminal domain contains an intrinsically disordered region and a folded segment. The disordered region has an autoinhibitory function and a dimerization interface, and the folded segment was found to have an allosteric site of acyl-CoA/CoA. When acyl-CoA levels increase, the binding of acyl-CoA with this non-catalytic site initiates allosteric activation. Enzyme activation is prevented until limiting acyl-CoA conditions, which allows CoA to act as a noncompetitive feedback inhibitor. For these reasons, it is proposed that the N-terminal domain of DGAT1 acts as a positive and negative regulator. <ref name=”Caldo”>Caldo, K., Acedo, J. Z., Panigrahi, R., Vederas, J. C., Weselake, R. J., & Lemieux, M. J. (2017). Diacylglycerol Acyltransferase 1 Is Regulated by Its N-Terminal Domain in Response to Allosteric Effectors. Plant physiology, 175(2), 667–680. https://doi.org/10.1104/pp.17.00934</ref>
+
Regulation of DGAT1 is thought to be performed by the hydrophilic N-terminal domain which regulates activity based on acyl-CoA/CoA levels. The N-terminal domain contains an intrinsically disordered region and a folded segment. The disordered region has an autoinhibitory function and a dimerization interface, and the folded segment was found to have an allosteric site of acyl-CoA/CoA. When acyl-CoA levels increase, the binding of acyl-CoA with this non-catalytic site initiates allosteric activation. Enzyme activation is prevented until limiting acyl-CoA conditions, which allows CoA to act as a noncompetitive feedback inhibitor. For these reasons, it is proposed that the N-terminal domain of DGAT1 acts as a positive and negative regulator. <ref name="Caldo">doi.org/10.1104/pp.17.00934</ref>
==Inhibitors==
==Inhibitors==

Revision as of 14:35, 27 April 2021

Human Diacylglycerol O-Transferase 1

Human Diacylglycerol O-Transferase 1 6VYI

Drag the structure with the mouse to rotate

References

[1] [10] [11] [12] [9] [13] [2] [4] [3]

  1. 1.0 1.1 Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese RV Jr. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13018-23. PMID:9789033
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Sui X, Wang K, Gluchowski NL, Elliott SD, Liao M, Walther TC, Farese RV Jr. Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme. Nature. 2020 May;581(7808):323-328. doi: 10.1038/s41586-020-2289-6. Epub 2020 May, 13. PMID:32433611 doi:http://dx.doi.org/10.1038/s41586-020-2289-6
  3. 3.0 3.1 Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res. 2008 Nov;49(11):2283-301. doi: 10.1194/jlr.R800018-JLR200. Epub 2008, Aug 29. PMID:18757836 doi:http://dx.doi.org/10.1194/jlr.R800018-JLR200
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Wang L, Qian H, Nian Y, Han Y, Ren Z, Zhang H, Hu L, Prasad BVV, Laganowsky A, Yan N, Zhou M. Structure and mechanism of human diacylglycerol O-acyltransferase 1. Nature. 2020 May;581(7808):329-332. doi: 10.1038/s41586-020-2280-2. Epub 2020 May, 13. PMID:32433610 doi:http://dx.doi.org/10.1038/s41586-020-2280-2
  5. doi.org/10.1104/pp.17.00934
  6. Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., Al-Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014). Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes, obesity & metabolism, 16(4), 334–343. https://doi.org/10.1111/dom.12221
  7. Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S., Suri, V., Qadri, A., Gareski, T., Jones, J., Hahm, S., Perreault, M., McKew, J., Shi, M., Xu, X., Tobin, J. F., & Gimeno, R. E. (2011). Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. The Journal of biological chemistry, 286(48), 41838–41851. https://doi.org/10.1074/jbc.M111.245456
  8. Haas, J. T., Winter, H. S., Lim, E., Kirby, A., Blumenstiel, B., DeFelice, M., Gabriel, S., Jalas, C., Branski, D., Grueter, C. A., Toporovski, M. S., Walther, T. C., Daly, M. J., & Farese, R. V., Jr (2012). DGAT1 mutation is linked to a congenital diarrheal disorder. The Journal of clinical investigation, 122(12), 4680–4684. https://doi.org/10.1172/JCI64873
  9. 9.0 9.1 Gluchowski, N. L., Chitraju, C., Picoraro, J. A., Mejhert, N., Pinto, S., Xin, W., Kamin, D. S., Winter, H. S., Chung, W. K., Walther, T. C., & Farese, R. V., Jr (2017). Identification and characterization of a novel DGAT1 missense mutation associated with congenital diarrhea. Journal of lipid research, 58(6), 1230–1237. https://doi.org/10.1194/jlr.P075119
  10. Caldo, K., Acedo, J. Z., Panigrahi, R., Vederas, J. C., Weselake, R. J., & Lemieux, M. J. (2017). Diacylglycerol Acyltransferase 1 Is Regulated by Its N-Terminal Domain in Response to Allosteric Effectors. Plant physiology, 175(2), 667–680. https://doi.org/10.1104/pp.17.00934
  11. Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S., Suri, V., Qadri, A., Gareski, T., Jones, J., Hahm, S., Perreault, M., McKew, J., Shi, M., Xu, X., Tobin, J. F., & Gimeno, R. E. (2011). Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. The Journal of biological chemistry, 286(48), 41838–41851. https://doi.org/10.1074/jbc.M111.245456
  12. Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., Al-Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014). Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes, obesity & metabolism, 16(4), 334–343. https://doi.org/10.1111/dom.12221
  13. Haas, J. T., Winter, H. S., Lim, E., Kirby, A., Blumenstiel, B., DeFelice, M., Gabriel, S., Jalas, C., Branski, D., Grueter, C. A., Toporovski, M. S., Walther, T. C., Daly, M. J., & Farese, R. V., Jr (2012). DGAT1 mutation is linked to a congenital diarrheal disorder. The Journal of clinical investigation, 122(12), 4680–4684. https://doi.org/10.1172/JCI64873

Student Contributors

  • Megan Leaman
  • Grace Hall
  • Karina Latsko

Proteopedia Page Contributors and Editors (what is this?)

Megan Leaman

Personal tools